Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (423) 423
science & technology (408) 408
life sciences & biomedicine (392) 392
simeprevir (385) 385
hepatitis c, chronic - drug therapy (280) 280
antiviral agents - therapeutic use (276) 276
hepatitis c (252) 252
male (237) 237
drug therapy, combination (222) 222
female (215) 215
middle aged (212) 212
hepatitis c virus (205) 205
sofosbuvir (205) 205
hepacivirus - genetics (197) 197
genotype (183) 183
gastroenterology & hepatology (178) 178
simeprevir - therapeutic use (158) 158
treatment outcome (151) 151
aged (145) 145
ribavirin - therapeutic use (142) 142
adult (128) 128
ribavirin (118) 118
hepatitis c - drug therapy (116) 116
antiviral agents - administration & dosage (115) 115
interferon (115) 115
hepacivirus - drug effects (114) 114
hepatitis (106) 106
antiviral agents (103) 103
antiviral agents - adverse effects (103) 103
sofosbuvir - therapeutic use (102) 102
hepatitis c, chronic - virology (91) 91
infectious diseases (91) 91
sulfonamides - therapeutic use (91) 91
pharmacology & pharmacy (84) 84
simeprevir - administration & dosage (83) 83
heterocyclic compounds, 3-ring - therapeutic use (80) 80
health aspects (75) 75
biological response modifiers (74) 74
interferon-alpha - therapeutic use (73) 73
simeprevir - adverse effects (72) 72
daclatasvir (70) 70
ribavirin - administration & dosage (70) 70
care and treatment (69) 69
uridine monophosphate - analogs & derivatives (69) 69
liver (66) 66
liver transplantation (66) 66
sustained virologic response (65) 65
analysis (63) 63
protease inhibitors (63) 63
hepatitis c, chronic - complications (62) 62
liver cirrhosis (61) 61
genetic aspects (59) 59
sofosbuvir - administration & dosage (59) 59
drug therapy (58) 58
transplantation (56) 56
polyethylene glycols - therapeutic use (54) 54
antiviral agents - pharmacology (50) 50
chronic hepatitis c (50) 50
protease inhibitors - therapeutic use (50) 50
uridine monophosphate - therapeutic use (50) 50
ribavirin - adverse effects (49) 49
telaprevir (48) 48
imidazoles - therapeutic use (46) 46
retrospective studies (46) 46
recombinant proteins - therapeutic use (45) 45
direct-acting antivirals (44) 44
recurrence (44) 44
virology (44) 44
ledipasvir (43) 43
gastroenterology and hepatology (42) 42
hepatitis c - virology (42) 42
viral nonstructural proteins - antagonists & inhibitors (42) 42
cirrhosis (41) 41
genotype & phenotype (41) 41
hepatology (40) 40
proteases (40) 40
sofosbuvir - adverse effects (40) 40
hepacivirus (39) 39
microbiology (39) 39
patients (39) 39
general & internal medicine (38) 38
hepacivirus - isolation & purification (38) 38
medicine, general & internal (38) 38
viral load (38) 38
virus diseases (36) 36
young adult (36) 36
hcv (35) 35
infections (35) 35
boceprevir (34) 34
medicine & public health (34) 34
abridged index medicus (33) 33
liver cirrhosis - drug therapy (33) 33
sulfonamides - administration & dosage (33) 33
viral nonstructural proteins - genetics (33) 33
immunology (32) 32
liver cirrhosis - virology (32) 32
viruses (32) 32
drug resistance, viral (31) 31
antiviral agents - economics (30) 30
surgery (30) 30
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (527) 527
German (11) 11
Japanese (9) 9
Portuguese (8) 8
Russian (8) 8
Hungarian (5) 5
Korean (4) 4
Czech (3) 3
French (3) 3
Spanish (3) 3
Chinese (2) 2
Polish (2) 2
Italian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir
by Jeffrey M. Collins and Kara Loren Raphael and Charles Terry and Emily J. Cartwright and Angana Pillai and Frank A. Anania and Monica M. Farley
Clinical infectious diseases, ISSN 1058-4838, 10/2015, Volume 61, Issue 8, pp. 1304 - 1306
BRIEF REPORTS | Simeprevir | HBV/HCV coinfection | Acute hepatitis | HBV reactivation | Sofosbuvir | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | Sofosbuvir - therapeutic use | Coinfection | Administration, Oral | Antiviral Agents - therapeutic use | Humans | Middle Aged | Risk Factors | Hepatitis B - virology | Hepatitis C, Chronic - virology | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Hepatitis B virus - physiology | Simeprevir - therapeutic use | Hepatitis B - complications | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Drug Therapy, Combination | Hepatitis | Care and treatment | Research | Hepatitis C virus | Disease prevention | Infectious diseases | Antibiotics | Drug therapy | Patients | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Sofosbuvir and simeprevir in hepatitis C genotype 1‐patients with end‐stage renal disease on haemodialysis or GFR <30 ml/min
by Nazario, Hector E and Ndungu, Milka and Modi, Apurva A
Liver international, ISSN 1478-3223, 06/2016, Volume 36, Issue 6, pp. 798 - 801
sofosbuvir | Cirrhosis | Chronic hepatitis C | end‐stage renal disease | simeprevir | severe renal impairment | kidney transplant | renal failure | liver transplantation | End-stage renal disease | Simeprevir | Kidney transplant | Severe renal impairment | Renal failure | Sofosbuvir | Liver transplantation | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Glomerular Filtration Rate | Liver Cirrhosis - complications | Humans | Middle Aged | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Simeprevir - adverse effects | Kidney Failure, Chronic - therapy | Simeprevir - administration & dosage | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Texas | Kidney Failure, Chronic - complications | Female | Aged | Sofosbuvir - adverse effects | Sustained Virologic Response | Drug Therapy, Combination | Renal Dialysis | Chronic kidney failure | Analysis | Liver | Transplantation of organs, tissues, etc | Genetic aspects | Hepatitis C | Liver cirrhosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection
by Zeuzem, Stefan and Hézode, Christophe and Bronowicki, Jean-Pierre and Loustaud-Ratti, Veronique and Gea, Francisco and Buti, Maria and Olveira, Antonio and Banyai, Tivadar and Al-Assi, M. Tarek and Petersen, Joerg and Thabut, Dominique and Gadano, Adrian and Pruitt, Ronald and Makara, Mihály and Bourlière, Marc and Pol, Stanislas and Beumont-Mauviel, Maria and Ouwerkerk-Mahadevan, Sivi and Picchio, Gaston and Bifano, Marc and M Phee, Fiona and Boparai, Navdeep and Cheung, Kin and Hughes, Eric A and Noviello, Stephanie and LEAGUE-1 Study Team
Journal of hepatology, ISSN 0168-8278, 2015, Volume 64, Issue 2, pp. 292 - 300
Gastroenterology and Hepatology | Daclatasvir | Simeprevir | Direct-acting antiviral | Genotype 1 | NS5A inhibitor | All-oral therapy | Hepatitis C virus | NS3 protease inhibitor | Hepatitis C virus; Genotype 1 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Drug Administration Schedule | Humans | Imidazoles - adverse effects | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | DNA, Viral - analysis | Genotype | Male | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Simeprevir - adverse effects | Dose-Response Relationship, Drug | Simeprevir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Ribavirin - administration & dosage | Adult | Female | Aged | Drug Monitoring | Health aspects | Genetic aspects | Index Medicus | Antiviral Agents | Hepatitis C, Chronic | Ribavirin | Life Sciences | Imidazoles | DNA, Viral | Hepacivirus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected with Hepatitis C and HIV
by Del Bello, David and Cha, Agnes and Sorbera, Maria and Bichoupan, Kian and Levine, Calley and Doyle, Erin and Harty, Alyson and Patel, Neal and Ng, Michel and Gardenier, Donald and Odin, Joseph and Schiano, Thomas D and Fierer, Daniel S and Berkowitz, Leonard and Perumalswami, Ponni V and Dieterich, Douglas T and Branch, Andrea D
Clinical infectious diseases, ISSN 1058-4838, 06/2016, Volume 62, Issue 12, pp. 1497 - 1504
sofosbuvir | simeprevir | HIV | hepatitis C | Infectious Diseases | Immunology | Life Sciences & Biomedicine | Microbiology | Science & Technology | HIV-1 | Hepatitis C - drug therapy | HIV Infections - epidemiology | Humans | Middle Aged | Male | Simeprevir - therapeutic use | Simeprevir - adverse effects | Viral Load | Simeprevir - administration & dosage | Hepatitis C - epidemiology | Female | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Antiviral Agents - therapeutic use | HIV Infections - virology | Risk Factors | Treatment Outcome | Antiviral Agents - administration & dosage | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Hepatitis C - virology | HIV Infections - drug therapy | New York City - epidemiology | Hepacivirus | Care and treatment | Research | Hepatitis C | HIV (Viruses) | Clinical trials | Hepatitis | Viruses | Human immunodeficiency virus--HIV | Pharmaceuticals | Virology | Index Medicus | and Commentaries
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Development of a simple HPLC–UV method for the determination of the hepatitis C virus inhibitor simeprevir in human plasma
by Nannetti, Giulio and Pagni, Silvana and Parisi, Saverio G and Alberti, Alfredo and Loregian, Arianna and Palù, Giorgio
Journal of pharmaceutical and biomedical analysis, ISSN 0731-7085, 03/2016, Volume 121, pp. 197 - 203
Therapeutic drug monitoring | HCV protease inhibitor | Simeprevir | Solid-phase extraction | TMC435 | HPLC–UV | HPLC-UV | Pharmacology & Pharmacy | Physical Sciences | Chemistry | Chemistry, Analytical | Life Sciences & Biomedicine | Science & Technology | Hepacivirus - drug effects | Simeprevir - chemistry | Simeprevir - blood | Simeprevir - pharmacology | Reproducibility of Results | Chromatography, High Pressure Liquid - methods | Spectrophotometry, Ultraviolet - methods | Drug Stability | Humans | Plasma - chemistry | Hepatitis C virus | Methods | High performance liquid chromatography | Phosphates | Protease inhibitors | Proteases | Analysis | Nitriles | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus‐infected patients with decompensated liver disease
by Lawitz, E and Poordad, F and Gutierrez, J. A and Kakuda, T. N and Picchio, G and Beets, G and Vandevoorde, A and Van Remoortere, P and Jacquemyn, B and Luo, D and Ouwerkerk‐Mahadevan, S and Vijgen, L and Van Eygen, V and Beumont, M
Journal of viral hepatitis, ISSN 1352-0504, 04/2017, Volume 24, Issue 4, pp. 287 - 294
sofosbuvir | simeprevir | hepatitis C | daclatasvir | Gastroenterology & Hepatology | Infectious Diseases | Life Sciences & Biomedicine | Science & Technology | Virology | Antiviral Agents - pharmacokinetics | United States | Humans | Middle Aged | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Imidazoles - pharmacokinetics | Simeprevir - adverse effects | Drug-Related Side Effects and Adverse Reactions - pathology | Simeprevir - pharmacokinetics | Simeprevir - administration & dosage | Adult | Female | Sofosbuvir - pharmacokinetics | Sofosbuvir - adverse effects | Imidazoles - adverse effects | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug-Related Side Effects and Adverse Reactions - epidemiology | Sofosbuvir - administration & dosage | Antiviral Agents - adverse effects | Aged | Hepatic Insufficiency - etiology | Hypertension | Antiviral agents | Medical research | Metabolites | Medicine, Experimental | Hepatitis C virus | Health aspects | Liver cirrhosis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Efficacy and safety of simeprevir with PegIFN/ribavirin in naïve or experienced patients infected with chronic HCV genotype 4
by Moreno, Christophe and Hezode, Christophe and Marcellin, Patrick and Bourgeois, Stefan and Francque, Sven and Samuel, Didier and Zoulim, Fabien and Grange, Jean-Didier and Shukla, Umesh and Lenz, Oliver and Ouwerkerk-Mahadevan, Sivi and Fevery, Bart and Peeters, Monika and Beumont, Maria and Jessner, Wolfgang
Journal of hepatology, ISSN 0168-8278, 2015, Volume 62, Issue 5, pp. 1047 - 1055
Gastroenterology and Hepatology | Simeprevir | Chronic | Response-guided | Efficacy | Safety | TMC435 (10/10) | Hepatitis C virus | Sustained virologic response | Protease inhibitor | Genotype 4 | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Polyethylene Glycols - adverse effects | Male | Hepatitis C, Chronic - ethnology | Secondary Prevention | Recombinant Proteins - adverse effects | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Hepacivirus - drug effects | Drug Administration Schedule | RNA, Viral - analysis | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Recombinant Proteins - administration & dosage | Interferon-alpha - administration & dosage | Drug Therapy, Combination - methods | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Interferon-alpha - adverse effects | Viral Load - drug effects | Viral Load - methods | Genetic aspects | Protease inhibitors | Hepatitis C | Proteases | Health aspects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection
by Fontana, Robert J and Brown, Robert S and Moreno‐Zamora, Ana and Prieto, Martin and Joshi, Shobha and Londoño, Maria‐Carlota and Herzer, Kerstin and Chacko, Kristina R and Stauber, Rudolf E and Knop, Viola and Jafri, Syed‐Mohammed and Castells, Lluís and Ferenci, Peter and Torti, Carlo and Durand, Christine M and Loiacono, Laura and Lionetti, Raffaella and Bahirwani, Ranjeeta and Weiland, Ola and Mubarak, Abdullah and ElSharkawy, Ahmed M and Stadler, Bernhard and Montalbano, Marzia and Berg, Christoph and Pellicelli, Adriano M and Stenmark, Stephan and Vekeman, Francis and Ionescu‐Ittu, Raluca and Emond, Bruno and Reddy, K. Rajender
Liver transplantation, ISSN 1527-6465, 04/2016, Volume 22, Issue 4, pp. 446 - 458
Gastroenterology & Hepatology | Transplantation | Life Sciences & Biomedicine | Surgery | Science & Technology | Recurrence | Liver Transplantation - adverse effects | Compassionate Use Trials | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Imidazoles - administration & dosage | Male | Hepatitis C, Chronic - complications | Simeprevir - therapeutic use | Simeprevir - adverse effects | Simeprevir - administration & dosage | Ribavirin - administration & dosage | Female | Retrospective Studies | Imidazoles - therapeutic use | Sofosbuvir - adverse effects | Sofosbuvir - therapeutic use | Hepacivirus - isolation & purification | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Imidazoles - adverse effects | Ribavirin - therapeutic use | Genotype | Treatment Outcome | Hepatitis C, Chronic - drug therapy | Antiviral Agents - administration & dosage | Drug Therapy, Combination - methods | Sofosbuvir - administration & dosage | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Liver Cirrhosis - pathology | Liver Diseases - surgery | Aged | Index Medicus | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Direct-acting antivirals for chronic hepatitis C
by Jakobsen, Janus C and Nielsen, Emil Eik and Feinberg, Joshua and Katakam, Kiran Kumar and Fobian, Kristina and Hauser, Goran and Poropat, Goran and Djurisic, Snezana and Weiss, Karl Heinz and Bjelakovic, Milica and Bjelakovic, Goran and Klingenberg, Sarah Louise and Liu, Jian Ping and Nikolova, Dimitrinka and Koretz, Ronald L and Gluud, Christian
Cochrane database of systematic reviews, ISSN 1469-493X, 06/2017, Volume 2017, Issue 6, pp. CD012143 - CD012143
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Hepacivirus - drug effects | Nucleic Acid Synthesis Inhibitors - therapeutic use | Nucleic Acid Synthesis Inhibitors - adverse effects | Antiviral Agents - therapeutic use | Humans | Hepatitis C, Chronic - complications | Hepatitis C, Chronic - drug therapy | Hepatitis C, Chronic - mortality | Simeprevir - therapeutic use | Cause of Death | Safety-Based Drug Withdrawals | Simeprevir - adverse effects | Randomized Controlled Trials as Topic | Placebos - therapeutic use | Antiviral Agents - adverse effects | Protease Inhibitors - adverse effects | Protease Inhibitors - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights